Clinical Trial Update: An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion [Phase 2]

View source ↗

Summary

Phase 2 study in Japanese patients with IPSS-R very low/low or intermediate risk myelodysplastic syndromes not requiring red blood cell transfusions evaluated t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2024-10-17